Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-547 · 1 trial · 2 indications
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 2: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 3: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 4: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 5: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 6: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 7: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 8: ABBV-547 & Placebo | EXPERIMENTAL | Japanese participants will receive either ABBV-547 or placebo. |
| Group 9: ABBV-547 & Placebo | EXPERIMENTAL | Han Chinese participants will receive either ABBV-547 or placebo. |
| Group 10: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 11: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-547 | DRUG | Parental Administration |
| ABBV-547 Placebo | DRUG | Parental Administration |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Part 1: BMI is \>= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
ABBV-547 is an investigational small molecule drug being developed by AbbVie for psoriasis. It is in Phase 1 clinical development and is administered as an injection. AbbVie is studying how the drug moves through the body, its adverse events, and how well it is tolerated in healthy volunteers and people with psoriasis.
ABBV-547 is being studied as a potential treatment for psoriasis. It is an investigational therapy in Phase 1 development, so it is not yet available as a marketed treatment. The ongoing study enrolls both healthy volunteers and participants with psoriasis to assess safety, tolerability, and how the drug moves through the body.
ABBV-547 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating the drug in psoriasis and in healthy volunteers.
ABBV-547 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for psoriasis or any other indication. The Phase 1 program is designed to evaluate safety, tolerability, and how the drug moves through the body.
ABBV-547 is being evaluated in one Phase 1 trial, NCT07232004, titled a study to evaluate how the study drug moves through the body, adverse events, and how the body tolerates ABBV-547 injections. The trial is active but not recruiting, is randomized, double-blind, and controlled, and has enrolled 142 participants across the United States and Japan.
The Phase 1 trial NCT07232004 enrolls adults aged 18 years and older of all sexes, including healthy volunteers and participants with psoriasis. The study is being conducted in the United States and Japan and is currently active but not recruiting new participants.